Topic: inter partes review
After a Friday ruling, Allergan's eye drug Restasis has to face the very patent challenge the company sought to prevent.
Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.
Allergan CEO Brent Saunders said it was "tenacity," not "desperation," that led the company to enter into the tribal licensing deal.
Allergan inked a settlement that gets one more would-be generic challenger off its radar, for now.
Eli Lilly has already foiled wannabe generic Alimta makers in court—and now it’s prevailed over one company taking the inter partes review route, too.
Sen. Claire McCaskill is moving to shut down the "brazen loophole" exposed in Allergan's tribal licensing deal.
Sanofi and Regeneron have gone the IPR route in their attempts to stop Amgen's patent infringement case over Dupixent. And so far, it hasn't worked.
Allergan is again being accused of using unfair tactics to dodge competition for its eye drug Restasis, this time for using bundled contracts.
It didn't take long for Congress to push back at Allergan's first-of-a-kind patent deal with the Saint Regis Mohawk Tribe.
Allergan says CFO Tessa Hilado, which came to Allergan three years ago, is retiring but agreed to stay on until her replacement is named.